Dermatol. praxi. 2013;7(2):66-68

The effect of naftifine on mycoses and its comparison to other antimycotics

MUDr.Jiří Slíva, Ph.D.
Ústavy farmakologie 2. a 3. LF UK, Praha

Locally acting antimycotics are commonly used in the treatment of superficial skin infections including tinea corporis, tinea cruris, and tinea

pedis etc. Naftifine is an allylamine substance, which has been used, like azoles, in many countries. Comparing to azoles, it should offer

a shorter duration of treatment. In this article, most relevant so far published clinical trials with naftifine in approved indications are discussed.

Keywords: naftifine, antimycotics, dermatomycoses, tinea, candidiasis

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. The effect of naftifine on mycoses and its comparison to other antimycotics. Dermatol. praxi. 2013;7(2):66-68.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stoughton RB, Sefton J, Zeleznick L. In vitro and in vivo cutaneous penetration and antifungal activity of naftifine. Cutis 1989; 44: 333-335. Go to PubMed...
    2. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997; 36: 788-792. Go to original source... Go to PubMed...
    3. Evans EG, James IG, Seaman RA, Richardson MD. Does naftifine have anti-inflammatory properties? A double-blind comparative study with 1% clotrimazole/1% hydrocortisone in clinically diagnosed fungal infection of the skin. Br. J Dermatol. 1993; 129: 437-442. Go to original source... Go to PubMed...
    4. Solomon BA, Lee WL, Geen SC, Suntharalingam K, Fikrig SM, Shalita AR. Modification of neutrophil functions by naftifine. Br. J Dermatol. 1993; 128: 393-398. Go to original source... Go to PubMed...
    5. Naftifine cream 1% versus clotrimazole cream 1% in the treatment of tinea pedis. Naftifine Podiatric Study Group. J Am Podiatr. Med. Assoc. 1990; 80: 314-318. Go to PubMed...
    6. Smith EB, Wiss K, Hanifin JM, et al. Comparison of once - and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis. J Am Acad. Dermatol. 1990; 22: 1116-1117. Go to original source... Go to PubMed...
    7. Naftifine gel in the treatment of tinea pedis: two double-blind, multicenter studies. Naftifine Gel Study Group. Cutis 1991; 48: 85-88. Go to PubMed...
    8. Ablon G, Rosen T, Spedale J. Comparative efficacy of naftifine, oxiconazole, and terbinafine in short-term treatment of tinea pedis. Int J Dermatol. 1996; 35: 591-593. Go to original source... Go to PubMed...
    9. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011; 10: 1282-1288. Go to PubMed...
    10. Jordon RE, Rapini RP, Rex IH, Jr. et al. Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea corporis. Int J Dermatol. 1990; 29: 441-442. Go to original source... Go to PubMed...
    11. Millikan LE, Galen WK, Gewirtzman GB, et al. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis. J Am Acad. Dermatol. 1988; 18: 52-56. Go to original source... Go to PubMed...
    12. Parish LC, Parish JL, Routh HB, et al. A double-blind, randomized, vehicle-controlled study evaluating the efficacy and safety of naftifine 2% cream in tinea cruris. J Drugs Dermatol. 2011; 10: 1142-1147. Go to PubMed...
    13. Meinicke K, Striegel C, Weidinger G. Treatment of dermatomycoses with naftifine therapeutic efficacy on application once daily and twice daily. Mykosen 1987; 30: 98-103.
    14. Effendy I, Friederich HC. Double-blind, randomized comparative study of naftifine solution (once dailyú and clotrimazole solution (twice daily) in the treatment of dermatomycoses. Mykosen 1987; 30: 104-111.
    15. Leiste D, Braun W, Fegeler W, et al. A double-blind clinical trial of fenticonazole (2) spray versus naftifine (1) spray in patients with cutaneous mycoses. Curr.Med.Res. Opin. 1989; 11: 567-575. Go to original source... Go to PubMed...
    16. Zaias N, Astorga E, Cordero CN, et al. Naftifine cream in the treatment of cutaneous candidiasis. Cutis 1988; 42: 238-240. Go to PubMed...
    17. Meyerson MS, Scher RK, Hochman LG, Cohen JL, Pappert AS, Holwell JE. Open-label study of the safety and efficacy of naftifine hydrochloride 1 percent gel in patients with distal subungual onychomycosis of the fingers. Cutis 1993; 51: 205-207. Go to PubMed...
    18. Klaschka F. Treatment of onychomycosis with naftifine gel. Mykosen 1987; 30: 119-123.
    19. Hira SK, Abraham MS, Mwinga A, Kamanga J, Schmidt C. Naftifine solution (1) in the treatment of pityriasis versicolor in Zambia. Mykosen 1986; 29: 378-381. Go to original source...
    20. Gold MH, Bridges T, Avakian E, et al. An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor. Skinmed. 2011; 9: 283-286. Go to PubMed...
    21. Gold MH, Bridges T, Avakian EV, Plaum S, Fleischer AB, Hardas B. An open-label pilot study of naftifine 1% gel in the treatment of seborrheic dermatitis of the scalp. J Drugs Dermatol. 2012; 11: 514-518. Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.